



European
Innovation
Council



VIVOSTAT TO JOIN EIC ACCELERATOR PILOT

For more than 4 years, we at Vivostat® together with Revolution® have been working to develop and implement a new product that is focused on reducing anastomotic leakage in gastrointestinal surgery. This journey eventually led to the development of Obsidian ASG®, which combines a new intra-anastomotic application technique with the advantage of a product that both seals and provides growth factors to accelerate the healing process. After an initial observational trial, it is indicated that the use of Obsidian ASG® reduced leakage by more than 50% in gastrointestinal resections.

Gastrointestinal resections often result in anastomotic leakages:

- It occurs in up to 19% of gastrointestinal surgeries with a mortality rate of up to 35%, making it the most dreaded complication following GI surgery
- Cost per patient is 4x higher compared to an uncomplicated procedure
- About 450.000 anastomosis procedures in Europe every year to treat colorectal cancer

We are now proud to announce that Vivostat, after a competitive process, has been accepted to be part of the Horizon 2020 – EIC Accelerator Pilot program and receive funding to further research Obsidian ASG® as an effective method for reducing the anastomotic leakage rate in GI surgery. The EIC Accelerator funding will allow Vivostat to demonstrate a large-scale clinical Phase III trial, which will take place at min. 12 different clinics across the EU with more than 400 patients participating. The research will seek to indicate Obsidian ASG® as an effective method for reducing the anastomotic leakage rate in gastrointestinal surgery. The purpose of this study will be to gain large-scale data highlighting the sealing and healing benefits of Obsidian ASG®, which leads to its ability to significantly reduce anastomotic leakage in GI surgery.

This great achievement is the next step for Vivostat® to provide a leading innovative product to combat anastomotic leakage. Furthermore, this pivotal clinical trial will set the way for Vivostat to enter all EU markets with Obsidian ASG® before or by 2023 and subsequently the US, Asia, and Oceania in 2025.

Obsidian Anastomotic SafeGuard
– A powerful and efficient tissue regeneration method

Colorectal Cancer

1.8M new cases per year

Inflammatory Bowel Disease

7M people affected worldwide

Esophageal Cancer

572K new cases per year

More than 4.8M patients will undergo surgical resection

Procedure example

Methods

Outcome

Anastomotic leakage in up to 19% of cases!

Obsidian ASG®

- ✓ 100% biocompatibility and autologous bioactive matrix
- ✓ At least 50% reduction of anastomotic leakages
- ✓ Only product for intra-anastomotic application
- ✓ Compatible with robotic-assisted systems
- ✓ Co-delivery option (e.g. antimicrobial agent)

Vivostat®

– An EUR 1.4B business opportunity

What is the EIC Accelerator Pilot?

"The EIC aims to identify and support breakthrough technologies and game-changing innovations to create new markets and scale up internationally"

The EIC Accelerator Pilot program is part of the EU's Horizon Europe initiative, offering funding and support to selected SME's and start-ups in the EU. With up to €2.5 million in funding for selectees, the EIC Accelerator Pilot gives a needed boost for both development and/or scale-up potential.